ArticlePharmaceutics2020
Topical Delivery of Carvedilol Loaded Nano-Transfersomes for Skin Cancer Chemoprevention.
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- Ultradeformable Vesicles for Wound Healing: Ethosomes, Transferosomes, and Transethosomes in Topical Drug Delivery.Pharmaceutics · 2026Review
- Recent Developments in Vesicular Nanocarriers for Targeted Drug Delivery in Breast Cancer.Current pharmaceutical design · 2026Review
- A dual edge-activation strategy for rhein bilosomes enhances intradermal delivery and anti-melanoma efficacy.Frontiers in pharmacology · 2026Article
- Transdermal Drug Delivery Systems: A Comprehensive Review of Mechanisms, Technologies, and Clinical Applications.Pharmaceutical research · 2025Review
- Carvedilol Prevents UV-Induced Immunosuppression and Skin Carcinogenesis through a Mechanism Independent of β-Blockade.JID innovations : skin science from molecules to population health · 2025Article
- Microneedle-Assisted Delivery of Curcumin: Evaluating the Effects of Needle Length and Formulation.Micromachines · 2025Article
- Transfersomes: Recent Advances, Mechanisms, Exhaustive Applications, Clinical Trials, and Patents.Current drug delivery · 2025Review
- Enhanced Transdermal Delivery of CilnidpinePharmaceutical nanotechnology · 2025Article
- Exploring the Therapeutic Potential of Vesicular Nanocarrier Systems for Elimination of Skin Cancer.Current medicinal chemistry · 2025Review
- Emerging Nanotechnology Involved in Skin Cancer: Pathogenesis, Biomarkers, Ethosomal Formulation and Future Perspective.Current pharmaceutical biotechnology · 2025Review
- Development and Evaluation of Methotrexate and Baicalin-Loaded Nanolipid Carriers for Psoriasis Treatment.Turkish journal of pharmaceutical sciences · 2024Article
- Unravelling the success of transferosomes against skin cancer: Journey so far and road ahead.Drug delivery and translational research · 2024Review
- Exploring the Therapeutic Potential of Natural Compounds in Psoriasis and Their Inclusion in Nanotechnological Systems.Antioxidants (Basel, Switzerland) · 2024Review
- Fabrication and application of targeted ciprofloxacin nanocarriers for the treatment of chronic bacterial prostatitis.International journal of pharmaceutics: X · 2024Article
- Transfersome, an ultra-deformable lipid-based drug nanocarrier: an updated review with therapeutic applications.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- The characteristics and biological activity enhancements of melatonin encapsulations for skin care product applications.International journal of pharmaceutics: X · 2023Article
- Innovative Topical Patches for Non-Melanoma Skin Cancer: Current Challenges and Key Formulation Considerations.Pharmaceutics · 2023Review
- QbD-Optimized, Phospholipid-Based Elastic Nanovesicles for the Effective Delivery of 6-Gingerol: A Promising Topical Option for Pain-Related Disorders.International journal of molecular sciences · 2023Article
- Production of Antioxidant Transfersomes by a Supercritical CONanomaterials (Basel, Switzerland) · 2023Article
- Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention.Nanomaterials (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
The β-blocker carvedilol has been shown to prevent skin carcinogenesis in vitro and in vivo. Since systemic absorption of the β-blocker may cause cardiovascular disturbance, we developed a carvedilol loaded transfersome for skin-targeted delivery. Transfersomes were prepared using phospholipids and surfactants at various ratios and characterized. One formulation (F18) selected for further analysis was composed of carvedilol, soy phosphatidylcholine, and Tween-80 at a ratio of 1:3:0.5, which had a particle size of 115.6 ± 8.7 nm, a zeta potential of 11.34 ± 0.67 mV, and an encapsulation efficiency of 93.7 ± 5.1%. F18 inhibited EGF-induced neoplastic transformation of mouse epidermal JB6 P+ cells at non-toxic concentrations, while only high concentrations induced cytotoxicity in JB6 P+ and human keratinocytes HaCaT. Compared to the free drug, F18 released through the dialysis membrane and permeated through the porcine ear skin at a slower rate, but similarly depositing the drug in the epidermis and dermis of the skin. Consistently, surface application of F18 on reconstructed full-thickness human skin showed slower drug permeation, while it suppressed ultraviolet-induced DNA damage, inflammatory gene expression, and apoptosis. These data indicate that transfersome is a promising topical delivery system of carvedilol for preventing ultraviolet-induced skin damage and carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.